VOR VS CLPT Stock Comparison

Performance

VOR
10/100

VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CLPT
10/100

CLPT returned -51.28% in the last 12 months. Based on SPY's performance of -13.03%, its performance is below average giving it a score of 10 of 100.

Technicals

VOR
10/100

VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

CLPT
14/100

CLPT receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

VOR
10/100

VOR has missed earnings 6 times in the last 20 quarters.

CLPT
10/100

CLPT has missed earnings 4 times in the last 20 quarters.

Profit

VOR
10/100

Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CLPT
10/100

Out of the last 20 quarters, CLPT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

VOR
43/100

VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

CLPT
44/100

CLPT has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Sentiment

VOR

"Sentiment" not found for VOR

CLPT
71/100

CLPT had a bullish sentiment score of 70.58% across Twitter and StockTwits over the last 12 months. It had an average of 3.18 posts, 0.79 comments, and 2.25 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Vor Biopharma Inc. Common Stock Summary

Nasdaq / VOR

Healthcare

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ClearPoint Neuro, Inc. Common Stock Summary

Nasdaq / CLPT

Healthcare

Medical - Devices

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Power up your portfolio